Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Drugs Made In America Acquisition Corp. (DMAA)

Drugs Made In America amends merger, sets $1.71 billion standalone valuation

Mixed Impact 4 of 5 m&a Written later

Drugs Made In America Acquisition Corp. and Power Analytics Global Corp. amended their merger agreement on October 13, 2026. If the APQC Acquisition is not completed by November 1, 2026, or another Reversion Event occurs, the closing valuation automatically falls from $2.85 billion to $1.71 billion on a standalone basis, and the APQC completion condition is removed.

Key points

  • Closing valuation drops from $2.85 billion to $1.71 billion on a standalone basis if a Reversion Event occurs.
  • Reversion Event triggers include APQC Acquisition not completed by November 1, 2026, termination of the APQC agreement, or an independent director determination that it cannot be completed.
  • Fairness opinion for the standalone valuation is expected from Joel A. Gallo on or before October 26, 2026, after the prior evaluator's engagement ended October 2, 2026.

The filing

CompanyDrugs Made In America Acquisition Corp. (DMAA)
Form8-K, current report
Filed with the SECOct 21, 2026, 5:27 PM ET
Accession number0001213900-26-111421

Items reported: 1.01 Material Definitive Agreement8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.